Home › Companies › ARTV

Artiva Biotherapeutics

ARTV Rare disease Lead: Phase 2 ★ Read the deep dive → 9 Biotech Distilled articles ↓

Dermatology Immunology Oncology Renal Cell

Most recent annual filing: 2026-03-15

Pipeline (14 active programs)

AlloNK

AB-101

Cell Target: CD20, CD19, CD16

Rheumatoid Arthritis Phase 1 GC Cell NCT06581562
Sjögren's Disease Phase 2 GC Cell
Systemic Sclerosis Phase 2 GC Cell
Idiopathic Inflammatory Myopathies Phase 2 GC Cell
Systemic Lupus Erythematosus Phase 1 GC Cell NCT06265220
Lupus Nephritis Phase 1 GC Cell NCT06265220
Pemphigus Vulgaris Phase 1 Integral Rheumatology & Immunology Specialists NCT06581562
ANCA-Associated Vasculitis Phase 1 Integral Rheumatology & Immunology Specialists NCT06581562

AB-201

Cell Target: HER2

AB-205

Cell Target: CD5

T-Cell Lymphoma GC Cell
T-Cell Acute Lymphoblastic Leukemia GC Cell

AB-202

Undisclosed indication GC Cell

Biotech Distilled coverage (9)

2026-08-07 UPDATE: Artiva (ARTV) - The CFO Clock Ran Out. Nobody Blinked. 🔒 Paid
2026-07-24 UPDATE: Artiva (ARTV) - Kolchinsky Keeps Buying. Now at 37.9%. 🔒 Paid
2026-06-16 UPDATE: Artiva (ARTV) - RA Capital Goes to 36.6%
2026-06-08 UPDATE: Artiva (ARTV) - RMAT Lands, EULAR Confirms, CFO Seat Still Empty
2026-05-19 UPDATE: Artiva (ARTV) - The CFO Walks. Ten Days After the Raise. 🔒 Paid
2026-05-09 UPDATE: Artiva (ARTV) - The Watch List Pays Off 🔒 Paid
2026-03-14 UPDATE: Artiva (ARTV) - The Autoimmune Pivot is Complete... 🔒 Paid
2026-02-28 UPDATE: Artiva (ARTV) - The CFO Red Flag is Gone... 🔒 Paid
2025-12-17 Artiva Biotherapeutics (ARTV): Scientific Due Diligence for AlloNK and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.